Stimulation of toll-like receptor 2 in mononuclear cells from HIV-infected patients induces chemokine responses: Possible pathogenic consequences

Clinical and Experimental Immunology

Volumn 138, Issue 1, 2004, Pages 116-121

  Heggelund, Lars ^a,b   Damas J K ^b   Yndestad, A ^b   Holm, A M ^a,b   Muller F ^c   Lien, E ^d,e   Espevik, T ^d   Aukrust, P ^a,b   Froland S S ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Chemokines; HIV AIDS; Innate immunity; Monocytes; Toll like receptors

Indexed keywords

BETA CHEMOKINE; CHEMOKINE; CHEMOKINE RECEPTOR CCR5; GAMMA INTERFERON; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TOLL LIKE RECEPTOR 2;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPATHOGENESIS; INFLAMMATION; MALE; MONOCYTE; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; RECEPTOR UPREGULATION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHEMOKINE CCL2; CHEMOKINES; FEMALE; HIV INFECTIONS; HUMANS; INTERFERON TYPE II; INTERLEUKIN-8; LEUKOCYTES, MONONUCLEAR; MACROPHAGE INFLAMMATORY PROTEIN-1; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; RANTES; RECEPTORS, CCR5; RECEPTORS, CELL SURFACE; RECOMBINANT PROTEINS; RNA, MESSENGER; RNA, VIRAL; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTORS; UP-REGULATION;

EID: 4644268688     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2004.02595.x     Document Type: Article

References (29)

1. Ozato K, Tsujimura H, Tamura T. Toll-like receptor signaling and regulation of cytokine gene expression in the immune system. Biotechniques 2002 (Oct Suppl.) 66-8,70,72.
2. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21:335-76.
3. Lawn SD, Butera ST, Folks TM. Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection. Clin Microbiol Rev 2001; 14:753-77.
4. Bafica A, Scanga CA, Schito ML, Hieny S, Sher A. Cutting edge: in vivo induction of integrated HIV-1 expression by mycobacteria is critically dependent on Toll-like receptor 2. J Immunol 2003; 171:1123-7.
5. Heggelund L, Muller F, Lien E et al. Increased expression of Toll-like receptor 2 on monocytes in HIV infection - possible role in inflammation and viral replication. Clin Infect Dis 2004; 39:264-9.
6. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999; 17:657-700.
7. Reinhart TA. Chemokine induction by HIV-1: recruitment to the cause. Trends Immunol 2003; 24:351-3.
8. Flo TH, Halaas O, Lien E et al. Human toll-like receptor 2 mediates monocyte activation by Listeria monocytogenes, but not by group B streptococci or lipopolysaccharide. J Immunol 2000; 164:2064.
9. Damas JK, Eiken HG, Oie E et al. Myocardial expression of CC- and CXC-chemokines and their receptors in human end-stage heart failure. Cardiovasc Res 2000; 47:778-87.
10. Lusso P. Chemokines and viruses: the dearest enemies. Virology 2000; 273:228-40.
11. Taub DD, Ortaldo JR, Turcovski-Corrales SM, Key ML, Longo DL, Murphy WJ. Beta chemokines costimulate lymphocyte cytolysis, proliferation, and lymphokine production. J Leukoc Biol 1996; 59:81-9.
12. Romano JW, Shurtliff RN, Lee EM et al. RANTES and MIP-1beta mRNA expression in human peripheral blood mononuclear cells: transcript quantification using NASBA technology. J Immunol Meth 2001; 255:115-24.
13. Verani A, Lusso P. Chemokines as natural HIV antagonists. Curr Mol Med 2002; 2:691-702.
14. Scala E, D'Offizi G, Rosso R et al. C-C chemokines, IL-16, and soluble antiviral factor activity are increased in cloned T cells from subjects with long-term nonprogressive HIV infection. J Immunol 1997; 158:4485-92.
15. + lymphocytes correlates with host genotype and rates of human immunodeficiency virus type 1 disease progression. J Infect Dis 2001; 183:1678-81.
16. Simmons G, Reeves JD, Hibbitts S et al. Co-receptor use by HIV and inhibition of HIV infection by chemokine receptor ligands. Immunol Rev 2000; 177:112-26.
17. Gross E, Amella CA, Pompucci L, Franchin G, Sherry B, Schmidtmayerova H. Macrophages and lymphocytes differentially modulate the ability of RANTES to inhibit HIV-1 infection. J Leukoc Biol 2003; 74:781-90.
18. Coffey MJ, Woffendin C, Phare SM, Strieter RM, Markovitz DM. RANTES inhibits HIV-1 replication in human peripheral blood monocytes and alveolar macrophages. Am J Physiol 1997; 272:L1025-L1029.
19. + T cells. Science 1995; 270:1811-5.
20. Izmailova E, Bertley FM, Huang Q et al. HIV-1 Tat reprograms immature dendritic cells to express chemoattractants for activated T cells and macrophages. Nat Med 2003; 9:191-7.
21. Reinhart TA, Fallert BA, Pfeifer ME et al. Increased expression of the inflammatory chemokine CXC chemokine ligand 9/monokine induced by interferon-gamma in lymphoid tissues of rhesus macaques during simian immunodeficiency virus infection and acquired immunodeficiency syndrome. Blood 2002; 99:3119-28.
22. Swingler S, Mann A, Jacque J et al. HIV-1 Nef mediates lymphocyte chemotaxis and activation by infected macrophages. Nat Med 1999; 5:997-103.
23. Vicenzi E, Alfano M, Ghezzi S et al. Divergent regulation of HIV-1 replication in PBMC of infected individuals by CC chemokines: suppression by RANTES, MIP-1alpha, and MCP-3, and enhancement by MCP-1. J Leukoc Biol 2000; 68:405-12.
24. Polo S, Veglia F, Malnati MS et al. Longitudinal analysis of serum chemokine levels in the course of HIV-1 infection. AIDS 1999; 13:447-54.
25. Aukrust P, Muller F, Froland SS. Circulating levels of RANTES in human immunodeficiency virus type 1 infection: effect of potent antiretroviral therapy. J Infect Dis 1998; 177:1091-6.
26. Appay V, Rowland-Jones SL. RANTES: a versatile and controversial chemokine. Trends Immunol 2001; 22:83-7.
27. Baltus T, Weber KS, Johnson Z, Proudfoot AE, Weber C. Oligomerization of RANTES is required for CCR1-mediated arrest but not CCR5-mediated transmigration of leukocytes on inflamed endothelium. Blood 2003; 102:1985-8.
28. Holme PA, Muller F, Solum NO, Brosstad F, Froland SS, Aukrust P. Enhanced activation of platelets with abnormal release of RANTES in human immunodeficiency virus type 1 infection. FASEB J 1998; 12:79-89.
29. von Hundelshausen P, Weber KS, Huo Y et al. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation 2001; 103:1772-7.